文献速递肝胆胰外科围术期管理与 ERAS

围术期地塞米松对胰十二指肠切除术后并发症的影响:多中心随机对照试验

The Effect of Perioperative Dexamethasone on Postoperative Complications After Pancreaticoduodenectomy: A Multicenter Randomized Controlled Trial.
PubMed 文献 · Ann Surg · 2024-02-22

这项多中心双盲随机对照试验在四个中国高容量胰腺中心纳入300例择期胰十二指肠切除术患者,随机接受0.2 mg/kg地塞米松或生理盐水安慰剂静脉推注。主要结局30天内综合并发症指数(CCI)评分在两组间无显著差异(均值差-3.8,95%CI -8.4至0.7,P=0.100)。主胰管≤3 mm亚组中地塞米松组CCI评分显著更低(均值差-6.4,95%CI -11.2至-1.6,P=0.009)。

要点

  • 围术期地塞米松未显著降低胰十二指肠切除术后30天内并发症。
  • 主胰管≤3 mm亚组中地塞米松组CCI评分显著更低(均值差-6.4,P=0.009)。
  • 主要并发症和术后胰瘘发生率两组无显著差异。

核心结论

  • 围术期地塞米松未显著降低胰十二指肠切除术后30天内并发症。

研究设计与样本

  • 多中心、双盲、随机对照试验,在四个中国高容量胰腺中心开展。
  • 计划纳入428例筛查患者,随机300例,改良意向性分析纳入265例(地塞米松组134例,安慰剂组131例)。
  • 干预为麻醉诱导后5分钟内静脉推注0.2 mg/kg地塞米松或生理盐水安慰剂。
  • 主要结局为术后30天内综合并发症指数(CCI)评分,按改良意向性分析原则分析。

主要发现

  • 30天内CCI评分均值(SD)地塞米松组14.0(17.5)vs 安慰剂组17.9(20.3),均值差-3.8(95%CI -8.4至0.7,P=0.100)。
  • 主要并发症(Clavien-Dindo分级≥III级)发生率地塞米松组12.7% vs 安慰剂组16.0%,风险比0.79(95%CI 0.44至1.43,P=0.439)。
  • 术后胰瘘发生率地塞米松组25.4% vs 安慰剂组31.3%,风险比0.81(95%CI 0.55至1.19,P=0.286)。
  • 主胰管≤3 mm亚组(n=202)中,地塞米松组CCI评分显著更低(均值差-6.4,95%CI -11.2至-1.6,P=0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of perioperative dexamethasone on postoperative complications after pancreaticoduodenectomy. BACKGROUND: The glucocorticoid dexamethasone has been shown to improve postoperative outcomes in surgical patients, but its effects on postoperative complications after pancreaticoduodenectomy are unclear. METHODS: This multicenter, double-blind, randomized controlled trial was conducted in four Chinese high-volume pancreatic centers. Adults undergoing elective pancreaticoduodenectomy were randomized to receive either 0.2 mg/kg dexamethasone or a saline placebo as an intravenous bolus within 5 minutes after anesthesia induction. The primary outcome was the Comprehensive Complication Index (CCI) score within 30 days after the operation, analyzed using the modified intention-to-treat principle. RESULTS: Among 428 patients for eligibility, 300 participants were randomized and 265 were included in the modified intention-to-treat analyses. One hundred thirty-four patients received dexamethasone and 131 patients received a placebo. The mean (SD) CCI score was 14.0 (17.5) in the dexamethasone group and 17.9 (20.3) in the placebo group (mean difference: -3.8; 95% CI: -8.4 to 0.7; P = 0.100). The incidence of major complications (Clavien-Dindo grade ≥III; 12.7% vs 16.0%, risk ratio: 0.79; 95% CI: 0.44 to 1.43; P = 0.439) and postoperative pancreatic fistula (25.4% vs 31.3%, risk ratio: 0.81; 95% CI: 0.55 to 1.19; P = 0.286) were not significantly different between the two groups. In the stratum of participants with a main pancreatic duct ≤3 mm (n = 202), the CCI score was significantly lower in the dexamethasone group (mean difference: -6.4; 95% CI: -11.2 to -1.6; P = 0.009). CONCLUSIONS: Perioperative dexamethasone did not significantly reduce postoperative complications within 30 days after pancreaticoduodenectomy.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Chen H, Wang Y, Jiang K, et al. The Effect of Perioperative Dexamethasone on Postoperative Complications After Pancreaticoduodenectomy: A Multicenter Randomized Controlled Trial. Ann Surg. 2024. PMID: 38385254. doi:10.1097/SLA.0000000000006240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。